Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

263P - Cross-sectional nationwide population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: a study of the French Network of Cancer Registries (FRANCIM)

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Emerline Assogba

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101224-101224. 10.1016/esmoop/esmoop101224

Authors

E. Assogba1, A. Woronoff2, A. Dumas3, C. Coutant4, I. Desmoulins1, S. Ladoire1, S. Dabakuyo-Yonli1

Author affiliations

  • 1 Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 2 CHRU Besancon - Hopital Jean Minjoz, Besancon/FR
  • 3 Inserm, Inserm, Pôle de Recherche Clinique, Paris/FR
  • 4 Centre Georges Francois Leclerc, Dijon/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 263P

Background

Over the last decades, living conditions of breast cancer (BC) survivors have received special attention particularly in young BC survivors who specially face difficulties related to fertility and sexuality.

Methods

Non-metastatic BC women diagnosed from 2009 to 2016, aged <= 40 years at diagnosis were identified through the FRANCIM Network. Participants completed self-report questionnaires including standardized measures (sexuality, Health Related Quality of Life (HRQoL), anxiety, depression, deprivation, social support and alcohol consumption); and fertility issues. Sexuality profiles were identified by ascending hierarchical classification.

Results

In total, 561 BC survivors from 14 French cancers Registries participated in the survey (response rate of 29%). The mean age at diagnosis was 35.9 (SD=3.8). Main tumors characteristics were AJCC stage 2-3 (61%), Hormone Receptor positive (76%), HER2 positive (24%), and Tumor grade >2 (91%). Most patients underwent lumpectomy (72%), chemotherapy (60%), radiotherapy (85%), endocrine therapy (71%) and few patients underwent targeted therapies (23%). More than 5 years after diagnosis, 48% reported sexual dysfunction. About 47% of women received information about the impact of BC treatment on fertility, and 34% reported that they received information about fertility preservation. Among 18% of women who had pregnancy project at diagnosis, 35% became pregnant after treatment. Ascending hierarchical clustering allowed to identify 3 distinct sexuality profiles from worse sexual function to the best respectively in 20%, 30% and 50%. Deprivation and treatment with endocrine therapy (especially tamoxifen) were associated with an increased risk of sexual dysfunction. The highest average score of HRQoL was in the physical functioning scale (82.2) and the lowest was in vitality (48.2).

Conclusions

This study showed that more than five year after diagnosis, BC survivors experienced difficulties related to sexuality. Specific interventions in this population should focus on in the management of sexual dysfunction and the improvement of the HRQoL.

Legal entity responsible for the study

Centre Georges-François Leclerc.

Funding

This work was supported by the Fonds de Dotation PFIZER INNOVATION FRANCE and the European Regional Development Fund (FEDER).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.